Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2012
12/20/2012US20120322769 Methods of reducing virulence in bacteria
12/20/2012US20120322768 Compounds, compositions and methods for treating protozoan infections
12/20/2012US20120322767 Formulations of bisphosphonates and vitamin d suiutable for intermittent intramuscular and subcutaneous administration
12/20/2012US20120322766 Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
12/20/2012US20120322764 Acyclic Nucleoside Phosphonate Derivatives and Medical Uses Thereof
12/20/2012US20120322763 Stable Bortezomib Formulations
12/20/2012US20120322762 Stable Bortezomib Formulations
12/20/2012US20120322761 Heterocyclic cetp inhibitors
12/20/2012US20120322760 Methods of treatment with a low molecular weight heparin composition
12/20/2012US20120322759 Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
12/20/2012US20120322757 Methods for Aloe Processing
12/20/2012US20120322756 Metabolic imprinting effects of structured lipids
12/20/2012US20120322755 Cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation
12/20/2012US20120322754 Novel use for scopolin and derivatives thereof
12/20/2012US20120322753 Production method of solid preparation and the solid preparations produced by the method
12/20/2012US20120322752 SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
12/20/2012US20120322751 use of rhamnolipids as a drug of choice in the case of nuclear disasters in the treatment of the combination radiation injuries and illnesses in humans and animals
12/20/2012US20120322750 Solubilization agent for solubilizing polyphenols, flavonoids and/or diterpenoid glucosides
12/20/2012US20120322743 Compositions and Methods for Diagnosing and Treating Melanoma
12/20/2012US20120322728 Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
12/20/2012US20120322727 Pharmaceutical Compositions for Intranasal Administration for the Treatment of Neurodegenerative Disorders
12/20/2012US20120322719 Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
12/20/2012US20120322718 Amygels in organic solvent for biomedical applications
12/20/2012US20120322717 Compounds and assays for controlling Wnt activity
12/20/2012US20120322674 Detecting cyp24 expression level as a marker for predisposition to cancer
12/20/2012US20120322155 Novel Biodegradable Elastomeric Scaffold for Tissue Engineering and Light Scattering Fingerprinting Methods for Testing the Same
12/20/2012US20120322024 Strip for the delivery of oral care compositions
12/20/2012US20120321727 Taste masking compositions and edible forms thereof
12/20/2012US20120321726 Berberine-containing pharmaceutical composition for inhibiting cancer stem cell growth or carcinoma metastasis and application thereof
12/20/2012US20120321720 Therapeutic application of parenteral krill oil
12/20/2012US20120321719 Sustained Delivery of Therapeutic Agents to an Eye Compartment
12/20/2012US20120321717 Devices and pharmaceutical compositions for enhancing dosing efficiency
12/20/2012US20120321716 Technology for preventing abuse of solid dosage forms
12/20/2012US20120321715 Micelles for the solubilization of gossypol
12/20/2012US20120321714 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof
12/20/2012US20120321713 Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
12/20/2012US20120321712 Pharmaceutical Composition
12/20/2012US20120321711 Direct compression polymer tablet core
12/20/2012US20120321710 Controlled Release and Taste Masking Oral Pharmaceutical Composition
12/20/2012US20120321708 Sustained-release formulations of topiramate
12/20/2012US20120321706 Novel gastroretentive dosage forms of poorly soluble drugs
12/20/2012US20120321704 Compound sea Cucumber Product, Preparation Method, and Dosage Forms Thereof
12/20/2012US20120321702 Pharmaceutical composition of lansoprazole
12/20/2012US20120321698 Inhalable pharmaceutical compositions
12/20/2012US20120321696 Accelerating Thrombus Resolution Through Augmentation of p53 Activity
12/20/2012US20120321695 Use of PVP-Iodine Liposomes for Treatment of Herpes
12/20/2012US20120321690 Adhesive patch
12/20/2012US20120321685 Compositions containing oils having a specific gravity higher than the specific gravity of water
12/20/2012US20120321678 Intra-articularly supplementation method for treating joint diseases and injuries
12/20/2012US20120321677 Coated solid preparation
12/20/2012US20120321674 Technology for Preventing Abuse of Solid Dosage Forms
12/20/2012US20120321673 Transdermal drug delivery system and method of using the same
12/20/2012US20120321670 Formulations of nano-carriers and methods of preparing the same
12/20/2012US20120321653 Novel chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof
12/20/2012US20120321647 Structured rna motifs and compounds and methods for their use
12/20/2012US20120321643 Anti-epidermal growth factor receptor antibodies and uses thereof
12/20/2012US20120321639 Methods and compositions for the inhibition of stat5 in prostate cancer cells
12/20/2012US20120321637 Combination cancer therapy with herv inhibition
12/20/2012US20120321635 Composition Containing Inhibitors of the Expression or Activity of SH3RF2 for Preventing or Treating Cancer
12/20/2012US20120321629 Stem cell factor inhibitor
12/20/2012US20120321625 Antibodies to ox-2/cd200 and uses thereof in inhibiting immune responses
12/20/2012US20120321622 Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases
12/20/2012US20120321615 Assay for Metastatic Colorectal Cancer
12/20/2012US20120321613 Molecular targets for healing or treating wounds
12/20/2012US20120321609 Method of treating psychological disorders
12/20/2012US20120321608 Detection of mutations in a gene associated with resistance to viral infection, oas1
12/20/2012US20120321604 Carrier comprising non-neutralised tocopheryl phosphate
12/20/2012US20120321603 Composition and method for stabilization and delivery of therapeutic molecules
12/20/2012US20120321602 Omega-3 fatty acid nutriceutical composition and optimization method
12/20/2012US20120321599 Herpes virus strains
12/20/2012US20120321596 Kit for adhering biological hard tissues
12/20/2012US20120321594 Methods of controlling axon or dendrite development of neuronal cells
12/20/2012US20120321590 Bridged polycyclic compounds
12/20/2012US20120321586 Surfactant composition
12/20/2012US20120321584 Processes for preparing amine salts of kmup-3 and use thereof
12/20/2012US20120321579 Surfactant compositions
12/20/2012US20120321575 Use of kif13a and ap-1 inhibitors for inhibiting melanogenesis
12/20/2012US20120321574 Anhydrous topical skin preparations
12/20/2012US20120321571 Paraben compositions
12/20/2012US20120321566 Inhibition of biofilm formation by 1,2,3,4,6-penta-o-galloyl-d-glucopyranose
12/20/2012US20120321565 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist
12/20/2012US20120321563 Carbonic Anhydrase Targeting Agents and Methods of Using Same
12/20/2012US20120321559 Hexahydro-pyrrolo-isoquinoline compounds
12/20/2012US20120321554 Plexin d1 as a target for tumor diagnosis and therapy
12/20/2012US20120321552 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
12/20/2012US20120318262 Pyrvinium Wound Treatment Methods and Devices
12/20/2012CA2850137A1 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
12/20/2012CA2844407A1 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
12/20/2012CA2839735A1 D-serine for the treatment of visual system disorders
12/20/2012CA2839675A1 Therapeutically active compositions and their methods of use
12/20/2012CA2839616A1 Therapeutically active compositions and their methods of use
12/20/2012CA2839438A1 Agents and methods for treating ischemic and other diseases
12/20/2012CA2839437A1 Antisense modulation of fibroblast growth factor receptor 4 expression
12/20/2012CA2839301A1 Nuclear receptor modulators and their use for the treatment and prevention of cancer
12/20/2012CA2839244A1 A nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine
12/20/2012CA2839134A1 Trimethylangelicin as cftr corrector in bronchial epithelial cells
12/20/2012CA2838945A1 Glioblastoma inhibiting compounds and their use
12/20/2012CA2838741A1 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
12/20/2012CA2838703A1 Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
12/20/2012CA2838680A1 1,3-dioxoindene derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for the antivirus containing the same as an activeingredient
1 ... 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 ... 7860